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Abstract
Purpose/objectives: The aim of this study is to analyze the results of exclusive interstitial brachytherapy (IBT) as a
conservative approach in the treatment of penile cancer confined to the glans or the shaft with long-term follow-
up in a single institution.
Materials/methods: Between July 1992 and November 2013, 73 consecutive patients with non-metastatic invasive
penile cancer were treated by Low dose rate (LDR) IBT in our institution. The localization of the primary lesion was
glands in 67 patients (91.8 %) and shaft in 6 patients (8.2 %). All 73 patients presented with squamous cell carcinoma
with grades of differentiation as follows: 34 patients with grade 1 (44.7 %), 9 patients with grade 2 (11.8 %), 9 patients
with grade 3 (11.8 %) and 21 patients unknown (28.8 %). Six patients (7.8 %) presented with in situ carcinoma, 55
patients (75,3 %) presented with T1, 11 patients (15 %) presented with T2, and one patient (1.3 %) presented with Tx.
Inguinal nodal dissection was performed in 29 patients (38.2 %); 13 patients (17.8 %) presented with histologically
confirmed positive ganglion. After circumcision, IBT was performed using a hypodermic needle. The median dose
delivered was 60 Gy (range, 40 to 70 Gy). The median activity of the iridium-192 wire was 1.12 mCi/cm, and the
median reference isodose rate was 0.4 Gy/h (range, 0.2–1.2). Patients with histological inguinal metastases received
external beam radiotherapy to the selected inguinal affected area with a median dose of 45 Gy (30–55 Gy).
Results: The median follow-up time was 51.8 months (range 34.4 to 68.7). The 5-year overall survival was 82.0 %,
with eight deaths from cancer and five non-cancer-related deaths. Disease-specific survival was 91.4 %, relapse-
free survival was 64.4 %, and local relapse-free survival as 74 %. Total or partial penile preservation was 87.9 % at
5-years. Complications rates at 5 years were 6.6 % urethral stenosis (five patients), two patients (2.6 %) with pain
related to sexual intercourse and four patients (5.3 %) with dysuria grade 2. Five patients (6.8 %) required penile
amputation for necrosis.
Conclusions: IBT provides good local control with organ preservation, excellent tolerance and low complication
rates in early-stage penile cancers.
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Introduction
Penile cancer is a rare tumor, with an incidence rate of
only 0.4 to 0.6 % of all malignancies that affect men in
Europe [1, 2]. The incidence rates are higher in develop-
ing countries [3]. Phimosis, poor hygiene, lack of
circumcision during childhood, human papilloma virus
16 (HPV), and high-risk sexual behavior have been pre-
viously established as known risk factors [3–6]. The
presence of metastatic disease in the lymph nodes is the
most important prognostic factor. Sentinel node biopsy
or inguinal lymph node dissection is recommended in
stages T1-T3 N0-X [7]. Historically, surgical treatment
has been performed on primary lesions with psycho-
logical alterations and physical morbidities, such as urin-
ary disorders [8, 9]. Conservative treatment must always
be performed during the early stages of disease [9], and
surgery is the treatment of choice after local failure. In
this sense, interstitial brachytherapy (IBT) is an excellent
alternative to radical procedures in early-stage penile
carcinoma due to the similar outcome and penile con-
servation rates of approximately 75 % that it affords
[10]. According to international recommendations, both
LDR and pulsed dose rate (PDR) modalities are used
to deliver this treatment [11]. We present a single-
institution experience based on 73 cases of invasive
penis cancer treated with interstitial brachytherapy
with curative intent as the primary treatment in our
center from 11/1992 to 11/2013.
Materials and methods
Study population and dataset
We recorded all of the patients treated at our institution
with a low dose of IBT with iridium-192 with curative
intent for squamous cell penile carcinoma from 11/1992
to 10/2013. Data were collected from paper and/or com-
puter medical records. The types of data collected from
each patient and tumor are reported in Table 1.
Brachytherapy technique treatment
Under general anesthesia, a radiation oncologist con-
ducts a clinical exam to define the clinical target volume
(CTV) that comprises primary tumor with 1 cm of mar-
gin in all directions and decides the number of plans
and the necessary needle to cover it. Two perforated
plates are positioned on both sides of the gland. Each
plate has equidistant holes ranging between 1 and
1.5 cm; the choice of a plate type varies depending on
the size of the lesion and the judgment of the radiation
oncologist. The number of active lines with iridium-192
used for the treatment of the patient is determined by
the radiation oncologist. Considering that contouring
and planning system had no tools to delineate tumor or
organs at risk, implant tried to cover primary tumor
with margin leaving if possible a free zone glans and
urethra without irradiation. The catheters are fixed to
both sides of the plate (Fig. 1). Paris system dosimetry
was used to perform dose calculation.
Statistical analysis
All patients were included in the analysis. The Kaplan-
Meier method was performed to estimate the overall sur-
vival (OS), overall specific survival (OSS), progression-free
survival (PFS), local disease-free survival (LFS), regional
disease-free survival (RFS), loco-regional disease-free sur-
vival (LRFS) and amputation-free survival (AFS). A log-






Yes 22 30.1 %
No 51 69.9 %
Vascular disease
Yes 27 36.9 %
No 46 63.0 %
Diabetes
Yes 10 13.9 %
No 63 78.8 %
Conjunctival tissue disease
Yes 3 4.1 %
No 70 95.9 %
Anatomopathological tumor grade
x 21 28.8 %
1 34 46.6 %
2 9 12.3 %
3 9 12.3 %
Localisation
Glans 67 91.8 %
Shaft 6 8.2 %
Necrosis
Yes 69 94.5 %
No 4 5.5 %
T
In situ 6 8.2 %
T1 55 75.3 %
T2 11 15 %
Tx 1 1.3 %
N
N+ 13 17.8 %
N- 60 82.2 %
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rank test was performed for all univariate comparative
survival. Multi-variable Cox regression for all survival
comparison were performed with all clinically interesting
variables (considered such if p < 0.2). P-values are two-
tailed and are considered statistically significant if < 0.05.
SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for
Windows, Version 21.0. Armonk, NY: IBM Corp.) was
used for statistical analysis. After treatment, local care and
anesthetics were used to relieve local symptomatology.
Results
Seventy-three patients were treated at Oscar Lambret
Cancer Center from 11/1992 to 11/2013.
Penile radiation treatment
The IBT median dose was 60 Gy (40–70), with more
than 75 % of patients receiving a dose at least equal to
60 Gy. The median wire number was 6 (2–17), the me-
dian plan number was 3 (1–4), the median wire length
was 4 cm (2–6), and the median activity was 1.11 mCi/
cm (0.590–1.710). IBT treatment characteristics is re-
ported in Table 2. After treatment, patients received
local care consisting in
Node treatment
Twenty-eight (38.5 %) patients had node surgery, 10
(13.7 %) had bilateral lymphadenectomy, and 18 (24.7 %)
had sentinel node surgery. Fourteen patients (19.17 %)
presented with one or more positive nodes after inguinal
examination and received external radiation therapy to
the selected inguinal-pelvic affected area with median
dose of 45 Gy (30–55Gy).
Toxicity (CTCAE-NCI 4.0 score)
Fifteen patients (20.5 %) presented with late toxicity:
nine patients (12.3 %) had late dermatitis (two with
grade 1, six with grade 2 and one with grade 3), four pa-
tients (5.5 %) presented with late urinary trouble, five
patients (6.8 %) presented with late stenosis, and two pa-
tients (2.1 %) presented with sexual pain.
Survival rates
The median follow-up time was 51.8 months (range
1.4–156.4). Nine patients (12.3 %) died during the
follow-up period, but only three died from cancer
(4.1 %), one died from renal failure, one died from head
and neck cancer, one died from acute respiratory failure,
one died from lung cancer, and two from unknown
causes. Forty-eight patients (65.8 %) had no evidence of
treatment failure, and 25 patients (34.2 %) presented
some type (local-regional-metastatic or mixed) of failure.
Locoregional control failure rate (LRCFR): 18 patients
(24.7 %) had local or loco-regional failures, and nine pa-
tients (12.3 %) had exclusive local failure; unfortunately,
there were no data to precise if local failure occurred in
the tumor bed or a distance. In regard to the regional
control failure rate (RCFR), nine patients (12.3 %) pre-
sented with regional or loco-regional failure, and seven
patients (9.6 %) presented with exclusive regional (node)
failure. Two patients (2.7 %) presented with distant
metastasis.
Amputation surgery
Twenty patients (27.4 %) had amputation surgery, five
(6.8 %) had total amputation surgery because of ne-
crosis, and 15 (20.5 %) surgeries were performed be-
cause of failure, with five total penile amputation
surgeries and 10 partial penile amputation surgeries
(unknown for the others).
The median overall survival (OS) was 132 months,
and OS rates were 95.3 % at 12 months, 85.4 % at 5 y
and 79.7 % at 10 years (Fig. 2). The mean disease-free
survival (DFS) was 90 months (2.6–127.9); DFS at 1, 5
and 10 years was 86.2, 66.3 and 52.5 %, respectively
(Fig. 2). The 1-, 5- and 10-year DFS for local controls
were 98.4, 88 and 84 %. The 1-, 5- and 10-year
amputation-free survival was 92.7, 69.1 and 60.0 %, re-
spectively. The 1-, 5- and 10-year regional control-free
Fig. 1 Brachytherapy technique treatment
Table 2 IBT treatment characteristics
Interstitial brachytherapy treatment
Median IBT dose 60 Gy (40 to 70Gy)
Isodose rate 0.2 to 1.2Gy/h
Median BT reference 0.4Gy/h
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survival (RCFS) was 91, 87.3 and 83.5 %, respectively.
The 1-, 5- and 10-year metastasis-free survival (MFS)
was 100, 95.9 and 95.9 %. The median overall specific
survival (OSS) was not discernable, but the mean OSS
was 150 months, and the 1-, 5- and 10-year rates were
100, 95 and 95 %, respectively.
Univariate and multivariate analysis
Node-positive disease at the time of diagnosis was asso-
ciated with a relatively poor DFS, with a median of
11.3 months (IC95 % 0.8–21.7) versus 123 months
(IC95 % (74.01–173.1) for node-negative disease (p =
0.002) and an RC with a mean RCFS of 140.6 months
(IC95 % 127.4–153.8) versus 105 months (IC95 % 64.5–
146.3) (p = 0.000) (Fig. 3). Diabetes was associated with
a worse amputation-free survival (p = 0.001), with a
mean survival of 78.7 months (IC95% (32.6–124.9)) ver-
sus 113.7 months (IC95 % (94.5–132.9)) in non-diabetic
patients and tumor necrosis with amputation-free sur-
vival of 20.1 months (IC95 % 0–40.8) (p = 0.000) versus
115.8 months (IC95 % 98.1–133.4). Tobacco use was
associated with a worse OS, with a mean OS of
110.8 months (IC95 % (82.46–139.2)) versus 145.6
(IC95 % 133.9–157.4) (p = 0.015) for non-tobacco users
and tumor necrosis with a mean OS of 63.9 months
(IC95 % 18,9–109) versus 139.6 months (IC95 % 127.8–
Fig. 2 Overall survival and disease free survival
Fig. 3 a) Disease free survival depending on nodal (blue line for patients node positive disease and green for patients node negative disease).
b) Regional disease free survival, blue line for patients without node disease and green one for node negative disease
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151.4) (p = 0.001). No factor was statistically significant
in multivariate analysis.
Discussion
Penis cancer is a rare disease, and no international
guidelines exist for making daily clinical decisions; the
majority of reports are from single-center retrospective
studies. Herein, we report our study conducted in a
series of 73 patients with local and locally advanced
squamous cell penile cancer treated with conservative
intention by IBT. The median overall survival (OS) was
132 months, and the OS rates were 85.4 % at 5 years
and 79.7 % at 10 years. The mean disease-free survival
(DFS) was 90 months (range 2.6–127.9); 1-, 5- and 10-
year DFS were 86.2, 66.3 and 52.5 %, respectively (Fig. 2).
The 1-, 5- and 10-year rate of local control was 98.4, 88
and 84 %, respectively. The 1-, 5- and 10-year
amputation-free survival was 92.7, 69.1 and 60.0 %, re-
spectively The 1-, 5- and 10-year regional control-free
survival (RCFS) was 91, 87.3 and 83.5 %, respectively.
Local control in early disease stages is equivalent when
IBT and surgery are compared; even if local control is
better in patients with all stages (T2 included) who have
undergone operation than those who have been treated
by brachytherapy after 5-years, conservative approaches
must always be proposed to the patients because of the
negative psychological impact on patients in the event of
mutilation due to a penile procedure [10]. Although the
presence of nodes plays an important role in the progno-
sis, local treatment is mandatory because no systemic
treatment has stopped or inhibited the growth of the
primary tumor in the penis.
Our local control (98.4, 88 and 84 % at 1, 5 and
10 years) and penis conservation rates (92.7, 69.1 and
60.0 % at 1, 5 and 10 years) are equivalent to those
already described in the literature or even higher, as in
this case of the study reported by Mazeron et al. [12]. In
that study, 78 % of local control rates with penis conser-
vation in 74 % of patients was reported for a series of 50
patients. Daly et al. [13] presented a series of 22 penile
cancer patients treated by IBT, with only one local recur-
rence. Rozan et al. [14] presented a large series of 259
patients treated by IBT (184 patients) or surgery and
IBT association (75 patients), with local control rates of
88 % at 3 years in both groups and penis conservation in
84 % of patients. Pimenta el al. [15] reported that only
one in their series of 25 patients experienced early local
failure (4 months after IBT) with a median follow-up
time of 9.2 years. Crook et al. [16] reported a local con-
trol rate of 88 % at 48 months in their series of 67 pa-
tients. Soria et al. [17] reported 71.4 % of local control
and penis conservation in their series of 35 penis cancer
patients treated exclusively with IBT. Delannes et al. [18]
presented local control rates with penile conservation in
67 % of all patients and 75 % of patients with T1-T2 dis-
ease with 23 % local necrosis (treated by local excision,
partial amputation or total amputation) in a series of 51
patients. De Crevoisier [19] observed a 10-year penile
cancer recurrence rate of 20 % in their series of 144 pa-
tients with invasive penis cancer treated exclusively with
IBT. Cook et al. [20] reported a cumulative incidence of
freedom from local failure of 85.3 % at 5 years. Delaunay
et al. [21] reported that 60 % of the patients in their
study had no recurrence after 80 months of follow-up.
In our series, the occurrence of late morbidity, mainly
urethral stenosis and gland necrosis, was similar to that
reported in historical data (Table 3). It is likely that the
retrospective character of the study led to an underesti-
mation of this measure, particularly in regard to urethral
stenosis. The main factors associated with necrosis are
the number of implanted wires, which is directly associ-
ated with tumor size and wire activity [14].
Lymph node invasion is the most important prognos-
tic factor in penis cancer. In this sense, a lymph node
examination before curative local treatment is necessary,
but clinical guidelines for this assessment do not exist.
When there are no clinically detectable affected nodes,
modified inguinal lymph node dissection (ILND) and dy-
namic sentinel-node biopsy (DSNB) can be performed;
when there are clinically detected affected inguinal
nodes, ILND must be performed. The retrospective
character of our study does not allow for the evaluation
of when ILND, modified ILND or DSNB were per-
formed. It is suggested that adjuvant radiotherapy can be
considered after complete ILND in patients with mul-
tiple or large inguinal lymph nodes or extra capsular
extension [7]. Postoperative inguinal irradiation was per-
formed independent of the number of positive nodes
(one or more) and the status of the node capsule. Our
results (1-, 5- and 10-year RCFS: 91, 87.3 and 83.5 %, re-
spectively) confirm excellent regional control. Lymph-
edema has not been assessed in our series. No lymph
node failure was observed when inguinal pN0 status was
observed at diagnosis.





















Urethral stenosis 18 % 12 % 9 % 30 % 43 % 16 % 1.3 % 45 % 21.1 % 6.8 %
Penis necrosis 4.8 % 16 % 12 % 21 % 1 % 6 % 1.3 % 23 % – 6.8 %
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Limitations
The main limitations of this analysis are the retrospect-
ive design and single-institution series.
In this regard, toxicity rates were likely under esti-
mated, including associated sexual pain, trophic alter-
ations after treatment, and urethral stenosis.
Pre-therapeutic nodal status was not evaluated uni-
formly (clinical examination, imaging, lymphadenectomy
and sentinel node sampling were all applied for node
evaluation).
IBT treatment can be performed using pulsed-dose-
rate (PDR) [22] and high-dose-rate (HDR) [23, 24]
brachytherapy techniques due to the cessation of
commercialization of iridium wires.
The early local control and toxicity rates observed in
our study are comparable to historical data using LDR
techniques taking into account that median follow up is
less than 5 years.
Conclusions
IBT is an excellent treatment option for localized penis
cancer in terms of local control and organ conservation.
In our study, local control, amputation and toxicity rates
were similar to those of previously published studies.
Due to the rarity of this cancer, patients from different
centers were pooled into groups to prospectively and ad-
equately describe dose prescription and dose delivery,
local control and toxicity rates, along with uniform daily
clinical practice results analysis.
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